|
業務類別
|
Biotechnology |
|
業務概覽
|
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors. |
| 公司地址
| 6055 Lusk Boulevard, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 450-6464 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.crinetics.com |
| 員工數量
| 594 |
| Mr. Tobin C. Schilke |
Chief Financial Officer and Principal Accounting Officer |
美元 452.25K |
29/04/2026 |
| Ms. Isabel Kalofonos |
Chief Commercial Officer |
-- |
29/04/2026 |
| Dr. Stephen F. Betz, PhD |
Chief Scientific Officer |
美元 520.00K |
29/04/2026 |
| Dr. R. Scott Struthers, PhD |
Director, President and Chief Executive Officer |
美元 718.50K |
29/04/2026 |
|
|
| Dr. Wendell D. Wierenga,PhD |
Chairman of the Board |
29/04/2026 |
| Mr. Matthew K. Fust |
Independent Director |
29/04/2026 |
| Ms. Caren Deardorf |
Independent Director |
29/04/2026 |
| Dr. Weston Nichols, PhD |
Independent Director |
29/04/2026 |
| Dr. R. Scott Struthers, PhD |
Director, President and Chief Executive Officer |
29/04/2026 |
| Ms. Stephanie S. Okey, M.S. |
Independent Director |
29/04/2026 |
| Dr. Rogerio Vivaldi Coelho, M.B.A.,M.D. |
Independent Director |
29/04/2026 |
| Dr. Camille L. Bedrosian,M.D. |
Independent Director |
29/04/2026 |
|
|
|
|
